Panel A: The current clinical approach involves an interview with a patient after a low platelet count was identified. If ITP (primary or secondary) is suspected, a standard therapy is prescribed and responses are evaluated only by post-treatment changes to platelet count. So far there are no pathways to stratify patients or reliable indicators to predict which line of treatment will work best.
Panel B: Our goal is to establish a pre-treatment set of evaluations that will ultimately help steer clinical decisions around treatments to result in better outcomes for the patient. To achieve this, blood samples 1 and 2 are taken before and after treatment and using methods listed under New Research Tools, we will evaluate new platelet and immune system parameters and develop a patient molecular profile. Clinical outcomes will be correlated with the molecular profile of the patient’s blood before/after treatment, and changes which correlate significantly with positive or negative outcomes will be identified. This new approach aims to better stratify patients and aid clinical management but also to revamp primary and secondary ITP categories based on disease pathology.